Published in Biochemistry on October 03, 1989
The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res (2008) 2.64
Topoisomerase II does not play a scaffolding role in the organization of mitotic chromosomes assembled in Xenopus egg extracts. J Cell Biol (1993) 2.30
DNA topoisomerase II, genotoxicity, and cancer. Mutat Res (2007) 1.95
The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage. J Mol Biol (2012) 1.87
Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res (1992) 1.74
Structure and function of type II DNA topoisomerases. Biochem J (1994) 1.73
Dynamics of human DNA topoisomerases IIalpha and IIbeta in living cells. J Cell Biol (2002) 1.67
DNA topoisomerase II alpha is the major chromosome protein recognized by the mitotic phosphoprotein antibody MPM-2. Proc Natl Acad Sci U S A (1993) 1.66
Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci U S A (1993) 1.60
Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci U S A (1989) 1.58
Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One (2010) 1.40
Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res (2013) 1.27
Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities. J Cell Biol (1997) 1.23
XK469, a selective topoisomerase IIbeta poison. Proc Natl Acad Sci U S A (1999) 1.21
Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions. Nucleic Acids Res (2000) 1.19
The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway. Proc Natl Acad Sci U S A (2003) 1.18
C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo. Nucleic Acids Res (2007) 1.17
Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies. Am J Pathol (1995) 1.17
(-)-Epigallocatechin gallate, a major constituent of green tea, poisons human type II topoisomerases. Chem Res Toxicol (2008) 1.15
Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor. Mol Cell Biol (1997) 1.13
Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci U S A (1991) 1.12
Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. Br J Cancer (1996) 1.12
The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs. Biochemistry (2006) 1.12
Bioflavonoids as poisons of human topoisomerase II alpha and II beta. Biochemistry (2007) 1.10
Bimodal recognition of DNA geometry by human topoisomerase II alpha: preferential relaxation of positively supercoiled DNA requires elements in the C-terminal domain. Biochemistry (2008) 1.09
Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells. Br J Cancer (1994) 1.07
Immunohistochemical study of DNA topoisomerase II in human gastric disorders. Am J Pathol (1996) 1.05
Association between the p170 form of human topoisomerase II and progeny viral DNA in cells infected with herpes simplex virus type 1. J Virol (1994) 1.03
Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme. Biochemistry (2005) 1.02
Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. Br J Cancer (1996) 1.00
Dietary polyphenols as topoisomerase II poisons: B ring and C ring substituents determine the mechanism of enzyme-mediated DNA cleavage enhancement. Chem Res Toxicol (2008) 0.99
Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity. Biochemistry (2008) 0.99
Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. Br J Cancer (1996) 0.98
The use of divalent metal ions by type II topoisomerases. Metallomics (2010) 0.98
Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast. J Clin Pathol (1995) 0.97
Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer (1995) 0.97
Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Biochem J (1996) 0.95
Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes. Br J Cancer (1993) 0.93
Cellular distribution of mammalian DNA topoisomerase II is determined by its catalytically dispensable C-terminal domain. Nucleic Acids Res (1997) 0.92
p53 regulates the minimal promoter of the human topoisomerase IIalpha gene. Nucleic Acids Res (1996) 0.91
Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc Natl Acad Sci U S A (1992) 0.89
The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells. Biochemistry (2008) 0.88
Sp1 mediates cell proliferation-dependent regulation of rat DNA topoisomerase IIalpha gene promoter. Biochem J (1999) 0.86
Modulation of gyrase-mediated DNA cleavage and cell killing by ATP. Antimicrob Agents Chemother (1998) 0.86
Anaphase chromatid motion: involvement of type II DNA topoisomerases. Biophys J (1995) 0.86
DNA topoisomerase IIalpha and -beta expression in human ovarian cancer. Br J Cancer (1999) 0.86
Active heterodimers are formed from human DNA topoisomerase II alpha and II beta isoforms. Proc Natl Acad Sci U S A (1996) 0.85
Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias. Br J Cancer (1992) 0.85
Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines. Br J Cancer (1995) 0.84
Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35. Clin Exp Immunol (2000) 0.84
Effect of ICRF-193, a novel DNA topoisomerase II inhibitor, on simian virus 40 DNA and chromosome replication in vitro. Mol Cell Biol (1992) 0.84
Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia. Mol Pharmacol (2013) 0.83
Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line. Br J Cancer (1993) 0.83
Developmental regulation of Drosophila DNA topoisomerase II. J Cell Biol (1991) 0.83
A topoisomerase II-like protein is part of an inducible DNA-binding protein complex that binds 5' of an immunoglobulin promoter. Nucleic Acids Res (1993) 0.82
Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites. Biochem J (2002) 0.82
Mutant isolation of mouse DNA topoisomerase II alpha in yeast. Nucleic Acids Res (1994) 0.81
Human cells express two differentially spliced forms of topoisomerase II beta mRNA. Nucleic Acids Res (1993) 0.81
Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening. PLoS One (2014) 0.80
Mechanisms regulating resistance to inhibitors of topoisomerase II. Front Pharmacol (2013) 0.80
Selective silencing of DNA topoisomerase IIβ in human mesenchymal stem cells by siRNAs (small interfering RNAs). Cell Biol Int Rep (2010) (2011) 0.79
Mechanisms of resistance to combinations of vincristine, etoposide and doxorubicin in Chinese hamster ovary cells. Br J Cancer (1995) 0.78
Comparison of in vitro activity of epipodophyllotoxins with other chemotherapeutic agents in human medulloblastomas. Br J Cancer (1991) 0.78
cin-4, a gene with homology to topoisomerase II, is required for centromere resolution by cohesin removal from sister kinetochores during mitosis. Genetics (2008) 0.78
Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G2/M arrest induced by topoisomerase II inhibitors. Br J Cancer (2003) 0.78
Contributions of the D-Ring to the activity of etoposide against human topoisomerase IIα: potential interactions with DNA in the ternary enzyme--drug--DNA complex. Biochemistry (2011) 0.78
The impact of the C-terminal domain on the interaction of human DNA topoisomerase II α and β with DNA. PLoS One (2011) 0.77
The analysis of mutant alleles of different strength reveals multiple functions of topoisomerase 2 in regulation of Drosophila chromosome structure. PLoS Genet (2014) 0.77
Topoisomerase II alpha mRNA and tumour cell proliferation in non-Hodgkin's lymphoma. J Clin Pathol (1997) 0.77
Efficacy of substituted 9-aminoacridine derivatives in small cell lung cancer. Invest New Drugs (2012) 0.77
CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors. Br J Cancer (2003) 0.77
The Identification of a Novel Mutant Allele of topoisomerase II in Caenorhabditis elegans Reveals a Unique Role in Chromosome Segregation During Spermatogenesis. Genetics (2016) 0.76
Use of a rapid throughput in vivo screen to investigate inhibitors of eukaryotic topoisomerase II enzymes. Antimicrob Agents Chemother (1998) 0.76
Tyrosine 656 in topoisomerase IIβ is important for the catalytic activity of the enzyme: Identification based on artifactual +80-Da modification at this site. Proteomics (2011) 0.75
Multidrug resistance characterization in multicellular tumour spheroids from two human lung cancer cell lines. Cancer Cell Int (2015) 0.75
Influence of topoisomerase II on the formation of oxygen-dependent radiation-induced DNA damage. Br J Cancer Suppl (1996) 0.75
Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol (1992) 3.42
Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant. Mol Cell Biol (1994) 3.27
Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene (1999) 3.23
Human RNase III is a 160-kDa protein involved in preribosomal RNA processing. J Biol Chem (2000) 2.88
Copper metallothionein of yeast, structure of the gene, and regulation of expression. Proc Natl Acad Sci U S A (1984) 2.74
Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ (1991) 2.20
Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity. J Biol Chem (2000) 2.00
Mitomycin C: a review. Cancer Treat Rev (1976) 1.92
Chemical synthesis and expression of a cassette adapted ubiquitin gene. J Biol Chem (1987) 1.84
Molecular cloning and complete amino-acid sequence of form-I phosphoinositide-specific phospholipase C. Nature (1988) 1.68
Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J Biol Chem (1987) 1.66
Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev (1979) 1.60
Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci U S A (1989) 1.58
Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem (1989) 1.57
Properties of cloned and expressed human RNase H1. J Biol Chem (1999) 1.52
Tumour necrosis factor (cachectin) induces phospholipase A2 activity and synthesis of a phospholipase A2-activating protein in endothelial cells. Biochem J (1988) 1.42
Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res (1992) 1.39
Comprehensive reform of the new drug regulatory process. Biotechnology (N Y) (1995) 1.38
Staurosporine inhibits protein kinase C and prevents phorbol ester-mediated leukotriene D4 receptor desensitization in RBL-1 cells. Mol Pharmacol (1988) 1.35
Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg Med Chem (1997) 1.31
Ubiquitin fusion augments the yield of cloned gene products in Escherichia coli. Proc Natl Acad Sci U S A (1989) 1.30
Cloning and expression of a yeast copper metallothionein gene. Gene (1984) 1.30
Yeast metallothionein function in metal ion detoxification. J Biol Chem (1986) 1.28
Dependence of mammalian DNA replication on DNA supercoiling. II. Effects of novobiocin on DNA synthesis in Chinese hamster ovary cells. Biochim Biophys Acta (1979) 1.27
Bleomycin, a review. J Med (1976) 1.26
Identification and isolation of a mammalian protein which is antigenically and functionally related to the phospholipase A2 stimulatory peptide melittin. J Biol Chem (1987) 1.26
Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Biochemistry (1997) 1.23
In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther (1998) 1.20
Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst (1989) 1.19
In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II). Cancer Res (1982) 1.18
Leukotriene D4 treatment of bovine aortic endothelial cells and murine smooth muscle cells in culture results in an increase in phospholipase A2 activity. J Biol Chem (1986) 1.17
Vitravene--another piece in the mosaic. Antisense Nucleic Acid Drug Dev (1998) 1.16
Ubiquitin-metallothionein fusion protein expression in yeast. A genetic approach for analysis of ubiquitin functions. J Biol Chem (1988) 1.15
Cleavage of single strand RNA adjacent to RNA-DNA duplex regions by Escherichia coli RNase H1. J Biol Chem (1997) 1.15
Analysis of parameters affecting the hemagglutination activity of Escherichia coli possessing colonization factor antigens: improved medium for observing erythrocyte agglutination. J Clin Microbiol (1981) 1.14
Cloning of a phospholipase A2-activating protein. Proc Natl Acad Sci U S A (1991) 1.13
Purification, characterization, and structural properties of a single protein from rat basophilic leukemia (RBL-1) cells possessing 5-lipoxygenase and leukotriene A4 synthetase activities. Mol Pharmacol (1986) 1.11
Investigating the structure of human RNase H1 by site-directed mutagenesis. J Biol Chem (2001) 1.09
Phase I-II study of mitomycin C topical therapy for low-grade, low stage transitional cell carcinoma of the bladder: an interim report. Cancer Treat Rep (1980) 1.09
Purification and characterization of a phosphoinositide-specific phospholipase C from guinea pig uterus. Phosphorylation by protein kinase C in vivo. J Biol Chem (1987) 1.09
Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res (1987) 1.09
In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res (1989) 1.08
Determinants of aminoglycoside-binding specificity for rRNA by using mass spectrometry. Proc Natl Acad Sci U S A (1999) 1.07
Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res (1985) 1.07
Gene synthesis, expression, and processing of human ubiquitin carboxyl extension proteins. J Biol Chem (1989) 1.07
Role of single-breath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients. Cancer Res (1979) 1.05
Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol (1990) 1.03
Elevated DNA topoisomerase II activity in nitrogen mustard-resistant human cells. Proc Natl Acad Sci U S A (1987) 1.03
Interactions of 5-lipoxygenase with membranes: studies on the association of soluble enzyme with membranes and alterations in enzyme activity. Biochemistry (1988) 1.02
Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II. Cancer Res (1990) 1.02
Glucocorticoid regulation of beta-adrenergic receptors in 3T3-L1 preadipocytes. Mol Pharmacol (1987) 1.02
Selective excision of gamma ray damaged thymine from the DNA of cultured mammalian cells. Biochim Biophys Acta (1975) 1.02
Vascular vasopressin receptors mediate phosphatidylinositol turnover and calcium efflux in an established smooth muscle cell line. Life Sci (1986) 1.01
Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des (1997) 1.01
In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol Res (1993) 1.01
Effect of leukotrienes, bradykinin and calcium ionophore (A 23187) on bovine endothelial cells: release of prostacyclin. Prostaglandins (1986) 1.00
Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol Res (1992) 1.00
Islet-activating protein inhibits leukotriene D4- and leukotriene C4- but not bradykinin- or calcium ionophore-induced prostacyclin synthesis in bovine endothelial cells. Proc Natl Acad Sci U S A (1986) 1.00
Leukotriene-induced hydrolysis of inositol lipids in guinea pig lung: mechanism of signal transduction for leukotriene-D4 receptors. Mol Pharmacol (1987) 0.99
Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds. J Med Chem (1987) 0.99
Use of COMPARE analysis to discover new natural product drugs: isolation of camptothecin and 9-methoxycamptothecin from a new source. J Nat Prod (2000) 0.99
Reduced formation of protein-associated DNA strand breaks in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res (1986) 0.99
Synthesis and structure-activity relationships of cytotoxic 7-hydroxy sterols. J Nat Prod (1994) 0.99
Cytotoxicity and antitumor activity of some tetrahedral bis(diphosphino)gold(I) chelates. J Med Chem (1990) 0.99
Peptidoleukotrienes: distinct receptors for leukotriene C4 and D4 in the guinea-pig lung. Biochem Biophys Res Commun (1983) 0.98
Isolation and characterization of a cDNA clone encoding rat 5-lipoxygenase. J Biol Chem (1988) 0.98
In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J Pharmacol Exp Ther (1995) 0.97
Biological activity of some coumarins from Sri Lankan Rutaceae. J Nat Prod (1994) 0.97
Sensitivity of human cell strains having different abilities to repair O6-methylguanine in DNA to inactivation by alkylating agents including chloroethylnitrosoureas. Cancer Res (1984) 0.97
Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage. Cancer Res (1982) 0.96
In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride. Cancer Res (1986) 0.95
Identification and isolation of a phospholipase A2 activating protein in human rheumatoid arthritis synovial fluid: induction of eicosanoid synthesis and an inflammatory response in joints injected in vivo. J Lab Clin Med (1990) 0.94
The influence of antisense oligonucleotide-induced RNA structure on Escherichia coli RNase H1 activity. J Biol Chem (1997) 0.94
Intermolecular cross-linking of DNA through bifunctional intercalation of an antitumor antibiotic, luzopeptin A (BBM-928A). Cancer Res (1983) 0.94
Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration. Biochem Pharmacol (2001) 0.94
A spectroscopic investigation of the metal binding site of bleomycin A2. The Cu(II) and Zn(II) derivatives. Biochim Biophys Acta (1978) 0.94
Etoposide (VP-16-213). Cancer Treat Rev (1979) 0.93
Antimicrobial and anticancer activity of tetrahedral, chelated, diphosphine silver(I) complexes: comparison with copper and gold. J Inorg Biochem (1988) 0.93
Expression and accurate processing of yeast penta-ubiquitin in Escherichia coli. J Biol Chem (1987) 0.93